Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Oliver Varette"'
Autor:
Nouf Alluqmani, Anna Jirovec, Zaid Taha, Oliver Varette, Andrew Chen, Daniel Serrano, Glib Maznyi, Sarwat Khan, Nicole E. Forbes, Rozanne Arulanandam, Rebecca C. Auer, Jean-Simon Diallo
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Oncolytic viruses (OVs) are promising anticancer treatments that specifically replicate in and kill cancer cells and have profound immunostimulatory effects. We previously reported the potential of vanadium-based compounds such as vanadyl sulfate (VS
Externí odkaz:
https://doaj.org/article/31b68295a0e340bdba30274553e1eac0
Autor:
Nicole Mittmann, Oliver Varette
Publikováno v:
Canadian Journal of Health Technologies. 2
Rare disease registries platforms serve an important function in assembling and linking real-world data for a broader population of patients—they collect real-world data to evaluate natural histories of disease, outcome measures, standards of care,
Autor:
Oliver Varette, Ashely Baddeley, Anabele Briere, Laurie Lambert, Tamara Rader, Julie Boucher, Nicole Mittmann
Publikováno v:
Canadian Journal of Health Technologies. 2
The prevalence of dementia is increasing annually and there is an ongoing, increasing, and evolving demand for enhanced care for dementia patients in Canada. CADTH facilitated a 5-member clinician panel to garner the perspectives of individuals who a
Autor:
Michael Ong, Bryan Lo, Marie-Ève Wedge, Carolina S. Ilkow, John C. Bell, Catia Cemeus, Oliver Varette, Aron Broom, Benjamin McSweeney, Bruce F. Burns, Harold L. Atkins, Brian J Laight, Julia Petryk, Brian A. Keller, Jean-Simon Diallo, Carolyn Nessim, Roberto A. Chica
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:1365-1378
Mutations in BRAF are the most prominent activating mutations in melanoma and are increasingly recognized in other cancers. There is currently no accepted treatment regimen for patients with mutant BRAFK601N melanoma, and the study of melanoma driven
Autor:
Anabel Bergeron, Vanessa Garcia, Rozanne Arulanandam, Fanny Tzelepis, Jean-Simon Diallo, Harsimrat Kaur Birdi, Anne Landry, Andrew Chen, Anna Jirovec, Oliver Varette, Keara Sutherland, Mohammed Selman, Zaid Taha, Nouf Alluqmani, Elizabeth Macdonald, Barbara C. Vanderhyden
Publikováno v:
Communications Biology, Vol 3, Iss 1, Pp 1-10 (2020)
Communications Biology
Communications Biology
We have demonstrated that microtubule destabilizing agents (MDAs) can sensitize tumors to oncolytic vesicular stomatitis virus (VSVΔ51) in various preclinical models of cancer. The clinically approved T-DM1 (Kadcyla®) is an antibody-drug conjugate
Publikováno v:
Virology. 538:24-34
Human adenovirus (HAdV) can cause severe disease and death in both immunocompromised and immunocompetent patients. The current standards of treatment are often ineffective, and no approved antiviral therapy against HAdV exists. We report here the des
Autor:
Brian A, Keller, Brian J, Laight, Oliver, Varette, Aron, Broom, Marie-Ève, Wedge, Benjamin, McSweeney, Catia, Cemeus, Julia, Petryk, Bryan, Lo, Bruce, Burns, Carolyn, Nessim, Michael, Ong, Roberto A, Chica, Harold L, Atkins, Jean-Simon, Diallo, Carolina S, Ilkow, John C, Bell
Publikováno v:
Journal of cancer research and clinical oncology. 147(5)
Mutations in BRAF are the most prominent activating mutations in melanoma and are increasingly recognized in other cancers. There is currently no accepted treatment regimen for patients with mutant BRAFWe developed and characterized the first patient
Autor:
Mohammed Selman, Andrew Chen, John C. Bell, Jean-Simon Diallo, Fabrice Le Boeuf, Hwan Hee Son, Debbie C. Crans, Fanny Tzelepis, Ramya Krishnan, Anabel Bergeron, Nader A. El-Sayes, Christopher Rousso, Oliver Varette
Publikováno v:
Molecular Therapy. 26:56-69
Oncolytic viruses (OV) are an emerging class of anticancer bio-therapeutics that induce antitumor immunity through selective replication in tumor cells. However, the efficacy of OVs as single agents remains limited. We introduce a strategy that boost
Autor:
Brian D. Lichty, Nader El Sayes, Oliver Varette, John C. Bell, Amelia Sadie Aitken, Marie-Claude Bourgeois-Daigneault, Guy Ungerechts, Adrian Pelin, Theresa Falls, Nikolas T. Martin, David F. Stojdl, Dominic G. Roy, Jean-Simon Diallo, Lauren Elizabeth St-Germain
Publikováno v:
Science translational medicine. 10(422)
Triple-negative breast cancer (TNBC) is an aggressive disease for which treatment options are limited and associated with severe toxicities. Immunotherapeutic approaches like immune checkpoint inhibitors (ICIs) are a potential strategy, but clinical
Autor:
Oliver Varette, John C. Bell, Fabrice Le Boeuf, Jiahu Wang, Tyler Milston Renner, Jean-Simon Diallo, Vera A. Tang, Marc-André Langlois
Publikováno v:
Vaccine. 34(42)
Vaccinia virus (VV) is an oncolytic virus that is currently being evaluated as a promising cancer vaccine in several phase I, II and III clinical trials. Although several quality control tests are performed on each new batch of virus, these do not ro